The impact of chronic untreated hyperglycaemia on the long-term stability of paraoxonase 1 (PON1) and antioxidant status in human sera

Journal of Clinical Pathology

Volumn 67, Issue 1, 2014, Pages 55-59

  Macharia, Muiruri ^a   Kengne, Andre P ^b   Blackhurst, Diane M ^c   Erasmus, Rajiv T ^a   Matsha, Tandi E ^d  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d CAPE PENINSULA UNIVERSITY OF TECHNOLOGY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84895056660     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2013-201646     Document Type: Article

References (27)

1. Blatter-Garin MC, James RW, Messmer S, et al. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein associated protein, K-45: identity of K-45 with paraoxonase. Eur J Biochem 1993;21:871-9. (Pubitemid 23050064)
2. Précourt LP, Amre D, Denis MC, et al. The three-gene paraoxonase family: physiologic roles, actions and regulation. Atherosclerosis 2011;214:20 -36.
3. Macharia M, Hassan MS, Blackhurst D, et al. The growing importance of PON1 in cardiovascular health: a review. J Cardiovasc Med 2012;13:443-53.
4. Gupta N, Gill K, Singh S. Paraoxonases: structure, gene polymorphism and role in coronary artery disease. Indian J Med Res 2009;130:361-8.
5. Bouman HJ, Schomig E, van Werkum JW, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 2011;17:110-6.
6. Aydin S, Ibrahim S, Aydin S, et al. The past and present of paraoxonase enzyme: its role in the cardiovascular system and some diseases. J Med Biochem 2012;31:161 -73.
7. Brackley M, Carro-Ciampi G, Stewart DJ, et al. Stability of the paraoxonase phenotyping ratio in collections of human sera with differing storage times. Res Commun Chem Pathol Pharmacol 1983;41:65-78. (Pubitemid 13035386)
8. Huen K, Richter R, Furlong C, et al. Validation of PON1 enzyme activity assays for longitudinal studies. Clin Chim Acta 2009;402:67-74.
9. Stenzel J, Worek F, Eyer P. Preparation and characterization of dialkylphosphorylobidoxime conjugates, potent anticholinesterase derivatives that are quickly hydrolyzed by human paraoxonase (PON1192Q). Biochem Pharmacol 2007;74:1390-400. (Pubitemid 47445445)
10. Beekhof PK, Gorshunska M, Jansen EHJM. Long term stability of paraoxonase-1and high-density lipoprotein in human serum. Lipids Health Dis 2012;11:53.
11. Mastorikou M, Mackness B, Liu Y, et al. Glycation of paraoxonase-1 inhibits its activity and impairs the ability of high-density lipoprotein to metabolize membrane lipid hydroperoxides. Diabet Med 2008;25:1049-55.
12. Hedrick CC, Thorpe SR, Fu MX, et al. Glycation impairs high-density lipoprotein function. Diabetologia 2000;43:312-20. (Pubitemid 30163474)
13. Zemlin AE, Matsha TE, Hassan MS, et al. HbA1c of 6.5% to diagnose diabetes mellitus -does it work for us?-The Bellville South Africa study. PloS one 2011;6: e22558.
14. Matsha TE, Hassan MS, Kidd M, et al. The 30-year cardiovascular risk profile of South Africans with diagnosed diabetes, undiagnosed diabetes, pre-diabetes or normoglycaemia: the Bellville, South Africa pilot study. Cardiovasc J Afr 2012;23:5-11.
15. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
16. Benzie IFF, Strain JJ. The Ferric reducing ability of plasma as a measure of 'Antioxidant power': The FRAP assay. Anal Biochem 1996;239:70-6.
17. Re R, Pellegrini N, Proteggente A, et al. Antioxidant activity applying an improved ABTS radical cation decolourization assay. Free Radic Biol Med 1999;26:1231-7. (Pubitemid 29262709)
18. Richter RJ, Furlong CE. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 1999;9:745-53. (Pubitemid 30011938)
19. Browne RW, Koury ST, Marion S, et al. Accuracy and biological variation of human serum Paraoxonase 1 activity and polymorphism (Q192R) by Kinetic Enzyme assay. Clin Chem 2007;53:310-7. (Pubitemid 46338276)
20. Jentzsch AM, Bachmann H, Fürst P, et al. Improved analysis of malondialdehyde in human body fluids. Free Rad Biol Med 1996;20:251-6. (Pubitemid 26021882)
21. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-10. (Pubitemid 16134762)
22. http://www.westgard.com/biological-variation-database-specifications/ print.htm (accessed Feb 2013).
23. Passey RB. Quality control for the clinical chemistry laboratory. In: Kaplan LA, Pesce JA, eds. Clinical chemistry: theory, analysis, and correlation. 3rd edn. St Louis: CV Mosby Company, 1996:385-91.
24. Hyang Shin A, Oh CJ, Park J-W. Glycation-induced inactivation of antioxidant enzymes and modulation of cellular Redox Status in lens cells. Arch Pharm Res 2006;29:577-81. (Pubitemid 44199359)
25. Lapolla A, Piarulli F, Sartore G. Advanced glycation end products and Antioxidant Status in Type 2 diabetic patients with and without peripheral artery disease. Diabetes Care 2007;30:670-6. (Pubitemid 46354351)
26. Savu O, Ionescu-Tirgoviste C, Atanasiu V, et al. Increase in total antioxidant capacity of plasma despite high levels of oxidative stress in uncomplicated type 2 diabetes mellitus. J Int Med Res 2012;40:709-16.
27. Palmieri B, Sblendorio V. Oxidative stress tests: overview on reliability and use Part I. Eur Rev Med Pharmacol Sci 2007;11:309-42. (Pubitemid 350213812)